Orforglipron: Oral GLP-1 Agonist for Obesity 💊

Created using ChatSlide

This lecture delves into the evolving role of GLP-1 agonists, starting from their roots in diabetes management to their emerging significance in obesity treatment. We explore Orforglipron, highlighting its oral administration benefits and distinct mechanism of action compared to injectable forms. An in-depth examination of the ATTAIN-1 Trial provides evidence of its safety and efficacy over 72 weeks. We'll discuss its impact on obesity treatment, emphasizing significant weight loss and...